Insider Buying: Dr. Martens (LON:DOCS) Insider Purchases £150.36 in Stock

Key Points

• Insider buying: Giles Wilson purchased 179 Dr. Martens shares at GBX 84 each, worth £150.36. He also bought 68,313 shares worth £49,185.36 in June.
• Stock performance: Dr. Martens shares rose 0.7% to GBX 88.80, with trading volume significantly above average. The company’s market capitalization was approximately £849.92 million.
• Analyst outlook: Analysts maintain a “Moderate Buy” consensus, with an average price target of GBX 105; recent targets range from GBX 100 to GBX 110.

Dr. Martens plc (LON:DOCS - Get Free Report) insider Giles Wilson acquired 179 shares of the company's stock in a transaction on Tuesday, August 11th. The stock was bought at an average price of GBX 84 per share, for a total transaction of £150.36.

Giles Wilson also recently made the following trade(s):

• On Thursday, June 25th, Giles Wilson bought 68,313 shares of Dr. Martens stock. The shares were bought at an average cost of GBX 72 per share, with a total value of £49,185.36.
• On Thursday, June 11th, Giles Wilson purchased 202 shares of Dr. Martens stock. The shares were bought at an average price of GBX 74 per share, for a total transaction of £149.48.

Dr. Martens Stock Up 0.7%

Shares of LON:DOCS traded up GBX 0.60 during midday trading on Thursday, hitting GBX 88.80. 18,918,002 shares of the stock were exchanged, compared to its average volume of 7,381,275. The company has a market capitalization of £849.92 million, a PE ratio of 37.00, a P/E/G ratio of 6.40 and a beta of 0.26. Dr. Martens plc has a 52-week low of GBX 59.15 and a 52-week high of GBX 100.87. The company has a debt-to-equity ratio of 108.85, a quick ratio of 1.13 and a current ratio of 2.61. The business's fifty day simple moving average is GBX 74.52 and its two-hundred day simple moving average is GBX 69.18.

Dr. Martens (LON:DOCS - Get Free Report) last issued its earnings results on Tuesday, May 19th. The company reported GBX 4.20 EPS for the quarter. Dr. Martens had a return on equity of 6.89% and a net margin of 3.11%.The firm had revenue of £764.90 million for the quarter. As a group, research analysts predict that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on DOCS. Berenberg Bank decreased their price target on Dr. Martens from GBX 114 to GBX 110 and set a "buy" rating for the company in a research note on Tuesday, May 19th. Royal Bank Of Canada reissued a "sector perform" rating and issued a GBX 100 price target on shares of Dr. Martens in a research report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Dr. Martens currently has a consensus rating of "Moderate Buy" and a consensus target price of GBX 105.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source